Erez Gai joins the PulmOne team after serving as Deputy CFO at the STL Group for 7 years. Prior to that he served as manager at Chaikin, Cohen, Rubin & Co. for 5 years. Erez is a Certified Public Accountant and holds an MBA in Financial Management from Tel Aviv University.
We’re pleased to announce our further expansion with the opening of our newest office in Tokyo, headed by Mr. Keisuke Hirai. Keisuke has over 25 years’ sales and marketing leadership experience in medical technology companies and will be responsible for MiniBox+ sales and service in Japan.
We’re excited to announce the opening of our newest subsidiary – PulmOne France. Based in Nimes, PulmOne France will be led by our VP Sales France, Mr. Julien Gineste, who joins us after serving as EMEA Sales Director for Inogen (NASDAQ: INGN). Julien will be responsible for our direct sales and customer service in France.
We welcome Dr. Hervé Nakache to PulmOne as VP Clinical Affairs & Product Management. Hervé has held several leadership roles in digital health, cardiology, urology and oncology for Israeli and European companies. He is a graduate of the Universite Claude Bernard Lyon 1 Medical School in France.
In a recently published paper describing a multi-center study conducted in Italy, the MiniBox+ was shown to be more feasible (significantly lower failure risk) and more convenient (number of attempts needed plus lower execution costs) than whole body plethysmography (“body box”). In addition, the lung volumes (LV) and diffusion capacity (DLco) measurements taken with the MiniBox+ were shown to be highly consistent with those obtained by the body box.
We’re happy to announce that due to our rapid growth and expansion, we recently opened an office in the Dallas-Fort Worth area in Texas. This office will serve as our US headquarters for both service and sales, providing support to our customers as well as to our sales team.
In a groundbreaking, multi-center study published in CHEST, “Validation of a Novel Compact System for the Measurement of Lung Volumes”, lung volumes measured with the MiniBox+™ were shown to be equivalent to body plethysmography (“body box”) in both healthy participants as well as those with lung disease. MiniBox+ lung volumes were more reproducible and correlated better with body plethysmography than the other leading office-based techniques.
We are proud to announce that the MiniBox Academy, our self-paced e-learning training and certification program, has been approved for 3.0 CEU’s by the American Association for Respiratory Care (AARC). The program is provided free of charge to all MiniBox/MiniBox+ customers.
We are pleased to announce the launch of MiniBox Academy, our innovative, self-paced e-learning training and certification program for MiniBox+ customers. MiniBox Academy is designed to improve PFT testing expertise, and ensure testing consistency, accuracy and reproducibility, as well as facilitate an outstanding patient experience.
PulmOne will now be offering the NIOX VERO® fractional exhaled nitric oxide (FeNO) airway inflammation measurement system as an add-on to the MiniBox+. The combined system will be offered to both companies’ current users as well as to new customers. See Press Release.
PulmOne has just launched sales to the Japanese market, under the leadership of Yan Zlicha and Koshi Tokuda. Based in Tokyo, Mr. Zlicha has successfully introduced a number of Israeli medical technologies to the Japanese market, including both imaging and diagnostic devices. Mr. Tokuda has over 30 years of sales management experience in the Japanese medical market.
PulmOne is participating as an exhibitor at three major industry meetings between October and December this year. We will be conducting live demo’s of the MiniBox at our booth at CHEST 2018 in San Antonio, ACAAI 2018 in Seattle, and AARC 2018 in Las Vegas. As always, we will be providing detailed information about our financing options and special offers.
Scott Yokobosky joins the PulmOne team with 20 years’ successful experience in several sales leadership positions in both pharmaceutical and medical device companies. We welcome him aboard as he leads our national sales team in North America.
PulmOne will be displaying the MiniBox next week at the Joint Congress of the American Academy of Allergy, Asthma, and Immunology and the World Allergy Organization in Orlando. As always, we will be demo-ing the MiniBox at our booth, and providing detailed information about our financing options and special offers for upcoming upgrades.
The MiniBox+ has received certification by the Japanese Notified Body – BSI, as well as the Korean Ministry Of Food And Drug Safety (MFDS), and is now approved for sale in these countries.
With the MiniBox+, hospitals and clinics can now perform complete Pulmonary Function Testing AND transfer the results to their EHR management system, keeping local and central systems synchronized. The MiniBox+ EHR connectivity module is HL7 compliant, easily configurable, and integrates with all major EHR systems.
The MiniBox+ now supports data entry of the 6-Minute Walk Test (6MWT) and allows for reporting results along with patient pulmonary function data. The 6MWT is a simple and objective measurement of functional capacity commonly used to assess patients with cardiovascular and/or respiratory diseases.
At the end of this month, PulmOne is exhibiting at two major congresses in the Allergy, Asthma and Pulmonary fields: The Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology in Boston, and the CHEST Annual Meeting in Toronto. As we do at all exhibitions, we will be performing live demo’s of the MiniBox at our booths.
PulmOne welcomes Michael Mesnik to its team as VP Marketing and Product Management. Michael has over 20 years’ experience in the respiratory diagnostic market, most recently as Director of Marketing at CareFusion. We are confident that Michael will play a key role in providing and implementing high quality solutions for our clients.
The latest MiniBox+ software upgrade enables fully automatic Lung Volume Measurements (LVM) and Diffusing Capacity (DLco), enabling testing by a wider range of medical staff team members.
PulmOne recently received two additional regulatory approvals for the sale of the MiniBox+. The MiniBox+ now holds the Health Canada License, and is also certified by TGA Australia. These approvals were obtained only four months after the MiniBox+ received FDA clearance, in October 2016.
PulmOne Advanced Medical Devices is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the MiniBox+ PFT device for sale in the USA. In addition to all the parameters measured by the MiniBox, the MiniBox+ has an integrated module for single breath Carbon Monoxide Diffusing Capacity (DLCO) testing. It offers fully automated measurements of Calculated DLCO, VA, and KCO.
With this clearance, PulmOne now offers complete pulmonary function testing in any clinical setting.
PulmOne participated in a number of exhibitions at scientific conferences both in Europe and the US in recent weeks. Visitors to our booth observed live MiniBox demonstrations of lung volume measurements with only 2 minutes of tidal breathing, and were impressed with the ease of use, automatic measurements, and portability of the device.
